Incyte Corp Ltd (INCY): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Incyte ( INCY) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.8%. By the end of trading, Incyte fell $0.81 (-1.7%) to $46.71 on light volume. Throughout the day, 1,184,811 shares of Incyte exchanged hands as compared to its average daily volume of 1,805,900 shares. The stock ranged in price between $46.14-$47.96 after having opened the day at $47.61 as compared to the previous trading day's close of $47.52. Other companies within the Health Care sector that declined today were: Mast Therapeutics ( MSTX), down 39.4%, Bio-Reference Labs ( BRLI), down 21.7%, Echo Therapeutics ( ECTE), down 15.5% and Heat Biologics ( HTBX), down 8.6%.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $7.7 billion and is part of the drugs industry. Shares are up 186.1% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Incyte a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally high debt management risk.

On the positive front, Oxygen Biotherapeutics ( OXBT), up 20.6%, BioScrip ( BIOS), up 17.3%, Prosensa Holding N.V ( RNA), up 15.5% and LipoScience ( LPDX), up 14.8% , were all gainers within the health care sector with Illumina ( ILMN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Cramer: There Should Be More Takeovers Where These Came From

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)